Abstract 304P
Background
Polygenic risk scores (PRS), which summarize the combined effect of multiple common risk variants, have been associated with elevated breast cancer risk in patients who lack any identifiable monogenic risk factors. One of the most well-validated PRSs in breast cancer to date is PRS313, which was developed from a Northern European biobank (n = 33,673 cases and n = 33,381 controls). However, subsequent work has demonstrated an attenuated effect of PRS313 in African females, raising generalizability concerns. In this work, we further investigate the generalizability of the PRS313 for American women of European (EA), African (AFR), Asian (EAA), and Latinx (HL) ancestry within one institution, leveraging a singular EHR system, genotyping platform, and quality control process.
Methods
Participants were females drawn from the UCLA ATLAS Biobank (N=18,627) from 2018-2023. SNPs were genotyped on a genome-wide array and imputed to the TOPmed reference panel. Breast cancer cases and controls were identified using ICD9 and ICD10 coding. We previously identified 5 Genetically Inferred Ancestries (GIA) based on Principal Component Analysis (PCA) and k-means clustering including African Americans (AA), Hispanic Latino Americans (HLA), East Asian Americans (EAA), European Americans (EA). Breast cancer subtypes were identified based on prescription patterns.
Results
We found that the PRS313 achieved overlapping AUCs in females of Lantix (AUC, 0.68; 95% CI, 0.65-0.71) and European ancestry (AUC, 0.70; 95% CI, 0.69-0.71) with lower AUCs for the AFR and EAA populations (AFR: AUC, 0.61; 95% CI, 0.56-0.65; EAA: AUC, 0.64; 95% CI, 0.60-0.680).
Conclusions
In summary, we found that PRS313 was significantly associated with breast cancer in American females of Hispanic and East Asian ancestry but with attenuated accuracy in women of African descent. Our results are consistent with prior studies on PRS313 and further highlight the need for ethnically diverse cohorts in developing and implementing polygenic risk scores.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
252P - Adjuvant chemotherapy in T1a/bN0 breast cancer patients with high oncotype DX recurrence scores (RS>25)
Presenter: Daniela Katz
Session: Poster session 02
253P - Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK
Presenter: Vasileios Angelis
Session: Poster session 02
254P - Effects of delaying adjuvant chemotherapy initiation on clinical outcomes in early triple-negative breast cancer patients
Presenter: Maria Eleni Hatzipanagiotou
Session: Poster session 02
255P - Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 02
256P - Evolution and risk stratification of adjuvant treatment strategies for early breast cancer: A Chinese perspective based on a national cancer database
Presenter: Ying Fan
Session: Poster session 02
257P - The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients: A real-world study
Presenter: Bo Lan
Session: Poster session 02
258P - Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
Presenter: Ricardo Brugés Maya
Session: Poster session 02
259P - Adjuvant doxorubicin-cyclophosphamide in early-stage breast cancer provides long-term cardiac safety
Presenter: Thiti Susiriwatananont
Session: Poster session 02
260P - Oncology efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
Presenter: Hee Jun Choi
Session: Poster session 02
261P - Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC patients
Presenter: Bernardo Rapoport
Session: Poster session 02